Is the third-line chemotherapy feasible for non-small cell lung cancer? A retrospective study
|
|
- Diane Logan
- 8 years ago
- Views:
Transcription
1 Turkish Journal of Cancer Volume 34, No.1, Is the third-line chemotherapy feasible for non-small cell lung cancer? A retrospective study MUSTAFA ÖZDO AN, MUSTAFA SAMUR, HAKAN BOZCUK, ERKAN ÇOBAN, MEHMET ARTAÇ, BURHAN SAVAfi Akdeniz University Faculty of Medicine, Department of Internal Medicine, Division of Medical Oncology, Antalya-Turkey ABSTRACT The purpose of this study was to determine the activity of third-line chemotherapy for non small lung cancer (NSCLC). This retrospective study included patients who had failed after a second-line chemotherapy. A total of 16 patients treated with third line chemotherapy were evaluated. Only one patient had a partial response (6.2%), with an additional 4 patients (24.8%) with disease stabilisation. The median time to progression was 46 days and the median overall survival time was 132 days after the onset of third-line therapy. The overall survival (OAS) after the third-line chemotherapy was linked with the presence of objective response achieved by the first-line treatment (p=0.009). Likewise, the progression free survival (PFS) was related with the presence of clinical benefit (complete + partial response + stable disease) after the first-line chemotherapy (p=0.044). However, other factors evaluated as potential predictors of PFS, or OAS were not found to be of significance. As a conclusion; highly selected patients, who have objective response to the first-line therapy may be offered a third-line chemotherapy regimen, provided that they have a good performance status. [Turk J Cancer 2004;34(1):19-23] KEY WORDS: Third-line chemotherapy, non-small cell lung cancer, survival INTRODUCTION Non-small cell lung cancer (NSCLC) accounts for approximately 75% of lung cancers. More than 60%-65% of patients present with locally advanced (stage IIIB) or metastatic (stage IV) disease and, thus, are not suitable for surgical treatment. The prognosis of patients with stage IIIB and IV disease is disappointing since less than 2% of patients with advanced disease survive 5 years (1). Stage IV non-small cell lung cancer is considered to be incurable with the current available therapies. Therefore, chemotherapy remains a therapeutic option mainly for symptom relief and improving quality of life in this patient population at the present time. However, a secondary aim may be a modest increase in survival (1-2). Current first-line treatment for advanced NSCLC is generally platinum-based combination chemotherapy, which produces 30-40% response rate and an overall median survival time of 8-10 months, with a 1-year survival rate of 30-40%. In a previous study, after a relapse following
2 20 Third-line Chemotherapy for NSCLC platinum-based chemotherapy, the median survival time for patients receiving best supportive care was only months. In this cohort of patients, one of the most important prognostic factors that predicts for longer survival in these patients is a good performance status (3-5). The value of second-line chemotherapy in advanced NSCLC has been debated until TAX 317 and TAX 320 provide the required evidence of benefit (6). In these trials, docetaxel significantly improved survival, compared with either best supportive care or control reference regimen. Quality of life was also increased with second line chemotherapy (6,7). The role of third-line chemotherapy for the treatment of patients with NSCLC that have relapsed after or failed to respond to second-line treatment is still unclear. Up to date, the only drug reported to have been used in clinical trials specifically for the third-line treatment of NSCLC is the orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) ZD 1839 (Iressa) (8,9). There are currently, no prospective studies to support the usage of third-line cytotoxic chemotherapy in NSCLC patients with either good or poor performance status. Thus, the purpose of this retrospective study is to review the evidence, in relation with the findings from our retrospective cohort of NSCLC patients who have had third line chemotherapy, and to evaluate the role of third-line chemotherapy in the management of advanced NSCLC patients who progress after second-line chemotherapy. PATIENTS AND METHODS 16 patients treated with third-line chemotherapy at the Akdeniz University Medical Oncology Department from June 1998 to January 2003, were retrospectively evaluated in this study. All patients had histological or cytological confirmation of metastatic NSCLC, and other than the current regimen, all had previously received two chemotherapy regimens, at least one being platinum-based. Baseline demographics including age, gender, performance status, date of diagnosis, disease status and tumor histology were obtained from the medical records of each patient. All treatments, best response, date of progression after the third-line chemotherapy, date of last visit to the cancer clinic or date last seen or date of death were recorded. Statistical analysis Survival curves were constructed, and median survival was calculated according to the Kaplan-Meier method. Response and clinical benefit by different lines of treatment (i.e. in the 1 st, 2 nd and 3 rd line setting) was tested by χ 2 test with linear-by-linear association. Overall survival after the third line treatment was calculated from the date of start of the third line treatment to the date of death or date last seen. Progression-free survival time was calculated from the date of start of the third line treatment to the day of progression or date last seen. Long-rank test was used to compare survival between groups. All p values are two sided and significant if less than SPSS (Statistical Package for Social Sciences) v.10.0 was used for the statistical analysis. RESULTS 16 patients treated with third line chemotherapy were evaluated. 7 patients were treated with weekly gemcitabine, 4 with docetaxel or paclitaxel, 3 with weekly vinorelbine, one with cisplatin+gemcitabine and one with docetaxel+vinorelbine. Patient characteristics are detailed in table 1. With the third line chemotherapy, one patient achieved a partial response (PR) (6.2%), four patients achieved stable disease (24.8%) with an overall clinic benefit of 31% (CR+PR+Stable disease). Among our cases, 2 (12.5%) and 8 (50%) had obtained a PR and clinical benefit, respectively, in the second-line, and 6 (37.5%) and 10 (62.5%) had attained a PR and clinical benefit, in the first-line setting. The response and clinical benefit to chemotherapy decreased by subsequent lines of treatment (Figure 1, p=0.024, χ 2 =5.12, df=1). Response to chemotherapy in the third line setting according to the different regimens used is summarized in table 1. The median time to progression was 46 days and the median overall survival time was 132 days after the third line therapy (Figures 2A and 2B). The progression free survival (PFS) after the third-line chemotherapy was linked with the presence of clinical benefit achieved by the first-line treatment (p=0.04). The median PFS in those who achieved a clinical benefit by
3 Özdo an et al. 21 Table 1 Patient characteristics Response to the third-line regimen General Characteristics Number (%) Min, Median, Max PR* SD** Progression Total 16 (100) Age 36, 51, 68 Sex Male 11 (69) Female 5 (31) Performance status (ECOG) 2 16 (100) Third-line regimens Weekly Gemcitabine 7 (44) 1 (6.2) 6 (37.2) Weekly Vinorelbine 3 (19) 2 (12.4) 1 (6.2) Taxanes 4 (25) 1 (6.2) 3 (18.6) Others 2 (12) 1 (6.2) 1 (6.2) Total 16 (100) 1 (6.2) 4 (24.8) 11 (69) * partial response, ** stable disease Fig 1. The association of line of chemotherapy administration with the response attained the first-line treatment was 62 days as opposed to 41 days in those who failed to achieve a clinical benefit (Figure 2D). However, other factors evaluated as potential predictors of PFS previously were not found to be associated with PFS in this study (Table 2). There was no response or stabilization of disease by the third line chemotherapy in any of the patients who failed to achieve a clinical benefit after the first-line treatment. Similarly, OAS after the third-line chemotherapy was linked with the presence of objective response obtained by the first-line chemotherapy (p=0.009). The median OAS in those who obtained an objective response after the first-line treatment was 168 days, versus 90 days in those who did not obtained an objective response (Figure 2C).
4 22 Third-line Chemotherapy for NSCLC A C B D Fig 2 (A, B, C, D). Survival after the 3 rd line chemotherapy. (A): Overall survival after the 3 rd line chemotherapy, (B): Progression free survival after the 3 rd line chemotherapy, (C): Overall survival with respect to the presence of partial response to 1 st line chemotherapy, (D): Progression free survival with respect to the presence of clinical benefit by 1 st line chemotherapy Table 2 Factors related with survival after the 3 rd line chemotherapy Progression free survival Overall survival General Features Statistics P Statistics P Age (<52 vs. 52 or elder) Gender Chemotherapy response to previous regimens Partial response to 1 st line chemotherapy (present vs. absent) Clinical benefit by 1 st line chemotherapy (present vs. absent) Partial response to 2 nd line chemotherapy (present vs. absent) Clinical benefit by 2 nd line chemotherapy (present vs. absent) DISCUSSION In this study, we present the results of 16 highly selected NSCLC patients treated with a third line regimen in a fiveyear period. Although there is no level 1 or 2 evidence to offer chemotherapy after the second-line treatment for NSCLC, when retrospectively evaluated, there may be a few patients who specifically ask for it, and subsequently be treated. For each case, the discussion on whether to treat
5 Özdo an et al. 23 or not was made between the patient and the treating physician, and the selection criteria is out of the scope of this manuscript. The new chemotherapeutic drugs (taxanes, vinorelbine, gemcitabine, and irinotecan) have shown reproducable response rates for the second-line therapy (10). We feel that the possibility of attaining a response with the drugs above may have been the main motivation for both the patients and their physicians for the possible consideration of a third-line chemotherapy in these NSCLC patients. The objective response rate of 6.2% in our cohort is obviously disappointing. Similarly, in the only retrospective analysis available in the literature on the usage of third-line chemotherapy in 43 non-small-cell-lung cancer patients by Massarelli et al. (11) a response rate of 2.3% after the third line treatment and 0% in the fourth-line setting was reported. Our study is important for the fact that we showed a relation between the presence of clinical benefit or objective response provided by the first-line chemotherapy and PFS or OAS after the third-line chemotherapy in NSCLC, respectively. So, the use of a third-line therapy may be desirable in patients who maintain a good performance, and in those who had an objective response to the first-line chemotherapy. Conversely, all patients who progressed on the first-line treatment did not respond to the third line regimen. However, it should be noted that present response rates are lower than those of a single agent, tyrosine kinase inhibitor of the epidermal growth factor receptor; Iressa. CONCLUSION With such low response rates, the usage of the thirdline chemotherapy with present drugs are not justified in NSCLC, in general. However, highly selected patients, who have objective response to the first-line therapy may be offered a third-line chemotherapy regimen, provided that they have a good performance status, and especially if the epidermal growth factor receptor inhibitor is not available. New drugs are urgently needed for the treatment of lung cancer patients. Hence, in our view, the value of the thirdline chemotherapy in NSCLC should be further tested in a prospective clinical trial. References 1. Parker SL, Tong T, Bolden et al. Cancer statistics, CA Cancer J Clin 1997;47: Ginsberg RJ, Vokes EE, Rosenzweig K. Cancer of the lung: non-small cell lung cancer. In: DeVita VTJ, Hellman S, Rosenberg SA. Cancer: Principles and Practice of Oncology. 6 th ed. Philadelphia: J.B. Lippincott Co., 2001; Shepherd FA. Second-line chemotherapy for non-small cell lung cancer: is more better or just simply more? Lung Cancer 2002;36: Lynch T. Review of two phase III randomized trials of singleagent docetaxel in previously treated advanced non-small cell lung cancer. Semin Oncol 2001;28: Kris MG. What does chemotherapy have to offer patients with advanced-stage non-small cell lung cancer? Semin Oncol 1998;25: Shepherd F, Dancey J, Ramlau R, et al. A prospective randomized trial of docetaxel (Taxotere) versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18: Fosella VF, Lynch T, Shepherd AF. Second line chemotherapy for NSCLC: establishing a gold standard. Lung Cancer 2002;38: Fukuoka M, Yano S, Giaccone G, et al. Final results from phase II trial of ZD 1839 (Iressa) for patients with advanced non-small cell lung cancer (IDEAL 1). Proc Am Soc Clin Oncol 2002;22:abstr Kris M, Natale R, Herbst R, et al. A phase II trial of ZD 1839 (Iressa) in advanced non-small cell lung cancer patients who had failed platinum and docetaxel-based regimens (IDEAL 2). Proc Am Soc Clin Oncol 2002;21:abstr Georgoulias VA. Second-line chemotherapy in relapsing or refractory patients with non-small cell lung cancer. Lung Cancer 2002;38:3: Massarelli E, Andre F, Liu DD, et al. A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer. Lung Cancer 2003;39:55-61.
Third-line or fourth-line chemotherapy in non-small-cell lung cancer patients with relatively good performance status
Available online at www.sciencedirect.com Journal of the Chinese Medical Association 74 (2011) 209e214 Original Article Third-line or fourth-line chemotherapy in non-small-cell lung cancer patients with
More informationNational Horizon Scanning Centre. Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer. December 2007
Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer December 2007 This technology summary is based on information available at the time of research and a limited literature search.
More informationEmerging Drug List GEFITINIB
Generic (Trade Name): Manufacturer: Gefitinib (Iressa ) formerly referred to as ZD1839 AstraZeneca NO. 52 JANUARY 2004 Indication: Current Regulatory Status: Description: Current Treatment: Cost: Evidence:
More informationMaintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai
Maintenance therapy in in Metastatic NSCLC Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Definition of Maintenance therapy The U.S. National Cancer Institute s
More informationTreatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost-Effectiveness
Department of Veterans Affairs Health Services Research & Development Service Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost-Effectiveness
More informationSummary ID# 13095. Clinical Study Summary: Study H3E-EW-B012
Page 1 Summary ID# 13095 Clinical Study Summary: Study H3E-EW-B012 First-line Treatment of Non-Small Cell Lung Cancer under Routine Conditions: Observational Study on Overall Survival Date summary electronically
More informationNCCN Non-Small Cell Lung Cancer V.1.2011 Update Meeting 07/09/10
Guideline Page and Request NSCL-3 Stage IA, margins positive delete the recommendation for chemoradiation. Stage IB, IIA, margins positive delete the recommendation for chemoradiation + Stage IIA, Stage
More informationActivity of pemetrexed in thoracic malignancies
Activity of pemetrexed in thoracic malignancies Results of phase III clinical studies of pemetrexed in malignant pleural mesothelioma and non-small cell lung cancer show benefit P emetrexed (Alimta) is
More informationTreatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost Effectiveness
Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost Effectiveness Investigators: Paul G. Shekelle, MD, PhD, Director Alicia R. Maher, MD Clinical
More informationEverolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer
LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer Everolimus plus exemestane for second-line
More informationREPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group
REPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group In the 2002 edition of the ASCO meeting, a total of 315 abstracts in the field of respiratory
More informationNon-small cell lung cancer, advanced or metastatic, switch-therapy after gemcitabine/carboplatin
COMPENDIA TRANSPARENCY TRACKING FORM DRUG: Docetaxel INDICATION: Non-small cell lung cancer, advanced or metastatic, switch-therapy after gemcitabine/carboplatin COMPENDIA TRANSPARENCY REQUIREMENTS 1 Provide
More informationOut-Patient Chemotherapy for Lung Cancer
Lung Cancer Out-Patient Chemotherapy for Lung Cancer Principles and practice JMAJ 46(12): 542 546, 2003 Shuichi YONEDA Director, Department of Pulmonary Medicine, Saitama Cancer Center Abstract: Recent
More informationDrug/Drug Combination: Bevacizumab in combination with chemotherapy
AHFS Final Determination of Medical Acceptance: Off-label Use of Bevacizumab in Combination with Chemotherapy for the Treatment of Metastatic Breast Cancer Previously Treated with Cytotoxic Chemotherapy
More informationEndpoint Selection in Phase II Oncology trials
Endpoint Selection in Phase II Oncology trials Anastasia Ivanova Department of Biostatistics UNC at Chapel Hill aivanova@bios.unc.edu Primary endpoints in Phase II trials Recently looked at journal articles
More informationIntroduction Objective Methods Results Conclusion
Introduction Objective Methods Results Conclusion 2 Malignant pleural mesothelioma (MPM) is the most common form of mesothelioma a rare cancer associated with long latency period (i.e. 20 to 40 years),
More informationAdvancing Personalized Therapy for Advanced Non-Small Cell Lung Cancer
GUIDING THE WAY White Paper Advancing Personalized Therapy for Advanced Non-Small Cell Lung Cancer is a serum proteomic test for patients with advanced non-small cell lung cancer that helps healthcare
More informationSECOND-LINE CHEMOTHERAPY in advanced non
Gemcitabine as Second-Line Treatment for Advanced Non Small-Cell Lung Cancer: A Phase II Trial By Lucio Crinò, Anna Maria Mosconi, Giorgio Scagliotti, Giovanni Selvaggi, Silvia Novello, Massimo Rinaldi,
More informationKRAS Mutation Analysis in Non-Small Cell Lung Cancer (NSCLC) Original Policy Date
MP 2.04.43 KRAS Mutation Analysis in Non-Small Cell Lung Cancer (NSCLC) Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature search/12:2013
More informationPharmacogenomic markers in EGFR-targeted therapy of lung cancer
Pharmacogenomic markers in EGFR-targeted therapy of lung cancer Rafal Dziadziuszko, MD, PhD University of Colorado Cancer Center, Aurora, CO, USA Medical University of Gdansk, Poland EMEA Workshop on Biomarkers,
More informationShifting the Paradigm for Maintenance Therapy for Non small-cell Lung Cancer
J Hong Kong Col Radiol. 2010;13(Suppl):S16-21 ORIGINAL ARTICLE Shifting the Paradigm for Maintenance Therapy for Non small-cell Lung Cancer VHF Lee Department of Clinical Oncology, Queen Mary Hospital,
More informationSecond-Line Therapy in Non Small-Cell Lung Cancer: The DELTA Between Different Genotypes Widens
VOLUME 32 NUMBER 18 JUNE 20 2014 JOURNAL OF CLINICAL ONCOLOGY ONCOLOGY GRAND ROUNDS Second-Line Therapy in Non Small-Cell Lung Cancer: The DELTA Between Different Genotypes Widens Alona Zer and Natasha
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline: PS Inj - Alimta Therapeutic Class: Antineoplastic Agents Therapeutic Sub-Class: Antifolates Client: PS Inj Approval Date: 8/2/2004 Revision Date: 12/5/2006 I. BENEFIT
More informationSur les nouveaux médicaments et les perspectives qu ils offrent (traitement à la carte et survie longue)
Sur les nouveaux médicaments et les perspectives qu ils offrent (traitement à la carte et survie longue) Professeur Jean Trédaniel Unité de cancérologie thoracique Hôpital Saint-Louis Comparison of Four
More informationMedication Policy Manual. Topic: Alimta, pemetrexed Date of Origin: May 12, 2010
Medication Policy Manual Policy No: dru213 Topic: Alimta, pemetrexed Date of Origin: May 12, 2010 Committee Approval Date: February 17, 2015 Next Review Date: February 2016 Effective Date: March 1, 2015
More informationHarmesh Naik, MD. Hope Cancer Clinic HOW DO I MANAGE STAGE 4 NSCLC IN 2012: STATE OF THE ART
Harmesh Naik, MD. Hope Cancer Clinic HOW DO I MANAGE STAGE 4 NSCLC IN 2012: STATE OF THE ART Goals Discuss treatment options for stage 4 lung cancer: New and old Discuss new developments in personalized
More informationAvastin in Metastatic Breast Cancer
Non-interventional study Avastin in Metastatic Breast Cancer ML 21165 / 2007 Clinical Study Report Synopsis ROCHE ML21165 / WiSP Project RH09 / V. 1.0 / 24.06.2013 ROCHE ML21165-2 - Name of Sponsor Roche
More informationDECISION AND SUMMARY OF RATIONALE
DECISION AND SUMMARY OF RATIONALE Indication under consideration Clinical evidence Crizotinib as 2nd line treatment for patients with anaplastic lymphoma kinase (ALK) positive lung cancer Score The application
More informationSYSTEMIC THERAPY FOR STAGE IV NON-SMALL CELL LUNG CANCER: AMERICAN SOCIETY OF CLINICAL ONCOLOGY CLINICAL PRACTICE GUIDELINE UPDATE
Which patients with stage IV NSCLC should be treated with chemotherapy? NSCLC with nonsquamous cell carcinoma, negative or unknown EGFR-sensitizing mutation and ALK gene rearrangement status, and PS 0-1
More informationAvastin in breast cancer: Summary of clinical data
Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading
More informationNon-Small Cell Lung Cancer
Non-Small Cell Lung Cancer in East tasia Chia-Chi (Josh) Lin, MD, PhD 林 家 齊 Director of Phase I Center, e Department of Oncology, National Taiwan University Hospital Clinical Associate Professor, Department
More informationSEARCH METHODOLOGY SEARCH STRATEGY #1 (SYSTEMATIC REVIEWS): PubMed 1966-3/16/2012 Cochrane Database of Systematic Reviews All years
Appendix A. Search Strategy for Systematic Reviews and Cost-Effectiveness Analyses (Search #1) TREATMENT OF METASTATIC NON-SMALL-CELL LUNG CANCER SEARCH METHODOLOGY SEARCH STRATEGY #1 (SYSTEMATIC REVIEWS):
More informationThird-line therapy in advanced non-small cell lung cancer
JBUON 3; (): 99-97 ISSN: 7-65, online ISSN: -693 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Third-line therapy in advanced non-small cell lung cancer Zhen Ying Geng,, Shun Chang
More informationCetuximab (Erbitux) MM.04.005 05/10/2005. HMO; PPO; QUEST Integration 01/01/2015 Section: Prescription Drugs Place(s) of Service: Office: Outpatient
Cetuximab (Erbitux) Policy Number: Original Effective Date: MM.04.005 05/10/2005 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 01/01/2015 Section: Prescription Drugs Place(s)
More informationNew Trends & Current Research in the Treatment of Lung Cancer, Pt. II
New Trends & Current esearch in the Treatment of Lung Cancer, Pt. II Howard (Jack) West, MD President & CEO, GACE Medical Director, Thoracic Oncology Program Swedish Cancer Institute Seattle, WA Cancer
More informationCytotoxic Therapy in Metastatic Breast Cancer
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Cytotoxic Therapy in Metastatic Breast Cancer Cytotoxic Therapy in Metastatic Breast Cancer Version 2002: von Minckwitz Versions
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_epithelial_ovarian_cancer 2/2001 11/2015 11/2016 11/2015 Description
More informationPharmacogenomic Approaches. Luis Paz-Ares Hospital Universitario Virgen del Rocio Seville, Spain
Pharmacogenomic Approaches Luis Paz-Ares Hospital Universitario Virgen del Rocio Seville, Spain Pharmacogenetics & Pharmacogenomics Medicine tailored to the individual Genetic information, including the
More informationFuture Directions in Clinical Research. Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center
Future Directions in Clinical Research Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center Outline 1. Status of Cancer Treatment 2. Overview of Clinical Research at UCDCC 3.
More informationCorporate Medical Policy
Corporate Medical Policy Ado-Trastuzumab Emtansine (Trastuzumab-DM1) for Treatment of File Name: Origination: Last CAP Review: Next CAP Review: Last Review: ado_trastuzumab_emtansine_(trastuzumab-dm1)_for_treatment_of_her-2_positivemalignancies
More informationGUIDELINES FOR THE MANAGEMENT OF LUNG CANCER
GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER BY Ali Shamseddine, MD (Coordinator); as04@aub.edu.lb Fady Geara, MD Bassem Shabb, MD Ghassan Jamaleddine, MD CLINICAL PRACTICE GUIDELINES FOR THE TREATMENT
More informationFrequency of NHL Subtypes in Adults
Chemotherapy Options Stephanie A. Gregory, M.D. The Elodia Kehm Professor of Medicine Director, Section of Hematology Rush University Medical Center Chicago, Illinois Frequency of NHL Subtypes in Adults
More informationThe following information is only meant for people who have been diagnosed with advanced non-small cell
Important information for people with advanced non-small cell lung cancer The following information is only meant for people who have been diagnosed with advanced non-small cell lung cancer (NSCLC). NSCLC
More informationSecond-Line Treatment Options in Non Small Cell Lung Cancer: A Comparison of Cytotoxic Agents and Targeted Therapies
Second-Line Treatment Options in Non Small Cell Lung Cancer: A Comparison of Cytotoxic Agents and Targeted Therapies Filippo de Marinis, a Stefano De Santis, a and Luigi De Petris b Current options for
More informationREFERENCE CODE GDHC212DFR PUBLICAT ION DATE JUNE 2013 GSK1572932A (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC212DFR PUBLICAT ION DATE JUNE 2013 GSK1572932A (NON-SMALL CELL LUNG CANCER) GSK1572932A (NON-SMALL CELL LUNG CANCER) - Executive Summary GSK1572932A (MAGE-A3): Key Metrics in NSCLC Markets
More informationStage 3 Lung Cancer - Know YourSurviving Conditions
Survival of Stage IIIb and IV Non-Small Cell Lung Cancer Patients on Best Supportive Care in Manitoba, Canada Erich Kliewer Alain Demers Sri Navaratnam Coreen Hildebrand Grace Musto Report for AstraZeneca
More informationCancer Treatments Subcommittee of PTAC Meeting held 18 September 2015. (minutes for web publishing)
Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015 (minutes for web publishing) Cancer Treatments Subcommittee minutes are published in accordance with the Terms of Reference for the
More informationJanuary 2013 LONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Summary. Contents
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Paclitaxel albumin (Abraxane ) as a substitute for docetaxel/paclitaxel for cancer Paclitaxel albumin (Abraxane ) as a substitute for docetaxel/ paclitaxel for
More informationLung Cancer: More than meets the eye
Lung Cancer Education Program November 23, 2013 Lung Cancer: More than meets the eye Shantanu Banerji MD, FRCPC Presenter Disclosure Faculty: Shantanu Banerji Relationships with commercial interests: Grants/Research
More informationA new score predicting the survival of patients with spinal cord compression from myeloma
A new score predicting the survival of patients with spinal cord compression from myeloma (1) Sarah Douglas, Department of Radiation Oncology, University of Lubeck, Germany; sarah_douglas@gmx.de (2) Steven
More informationOvarian Cancer and Modern Immunotherapy: Regulatory Strategies for Drug Development
Ovarian Cancer and Modern Immunotherapy: Regulatory Strategies for Drug Development Sanjeeve Bala, MD, MPH Ovarian Cancer Endpoints Workshop FDA White Oak September 3, 2015 Overview Immune agents from
More informationAvastin in breast cancer: Summary of clinical data
Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading
More informationRecommendation Strength Strong, supported by the evidence and expert consensus. Recommendation Benefit/Harm Evidence Quality
CHEMO- AND TARGETED THERAPY FOR WOMEN WITH HER2 NEGATIVE (OR UNKNOWN) ADVANCED BREAST Benefit/Harm Evidence Quality 1: Endocrine therapy, rather than chemotherapy, should be offered as the standard firstline
More informationEvolving Treatment Paradigms in Non-Small Cell Lung Cancer
PRINTER-FRIENDLY VERSION AT PHARMACYPRACTICE NEWS.COM Evolving Treatment Paradigms in Non-Small Cell Lung Cancer CALEB T. CHU, MD, MPH Postdoctoral Fellow Department of Thoracic/Head and Neck Medical Oncology
More information( targeted therapy ) ( oncogenesis ) ( epidermal. growth factor receptor tyrosine kinase inhibitor EGFR-TKI ) ( epidermal growth
2008 19 8-13 growth factor receptor tyrosine kinase inhibitor EGFR-TKI ) ( targeted therapy ) ( oncogenesis ) ( epidermal factor receptor monoclonal antibody EGFR-moAb ) growth factor monoclonal antibody
More informationCorporate Medical Policy
Corporate Medical Policy Molecular Analysis for Targeted Therapy for Non-Small Cell Lung File Name: Origination: Last CAP Review: Next CAP Review: Last Review: molecular_analysis_for_targeted_therapy_for_non_small_cell_lung_cancer
More informationBackground. t 1/2 of 3.7 4.7 days allows once-daily dosing (1.5 mg) with consistent serum concentration 2,3 No interaction with CYP3A4 inhibitors 4
Abstract No. 4501 Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a Phase III randomized, open-label, multicenter trial R. Motzer, D.
More informationL Lang-Lazdunski, A Bille, S Marshall, R Lal, D Landau, J Spicer
Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine and systemic chemotherapy in malignant pleural mesothelioma. A 10-year experience. L Lang-Lazdunski, A Bille, S Marshall, R Lal,
More informationProposal for Tyrosine Kinase Inhibitors for Non Small Cell Lung Cancer
31 May 2012 Proposal for Tyrosine Kinase Inhibitors for Non Small Cell Lung Cancer PHARMAC is seeking feedback on a proposal to: fund gefitinib (Iressa) as a first line treatment for patients with locally
More informationCancer Treatments Subcommittee of PTAC Meeting held 2 March 2012. (minutes for web publishing)
Cancer Treatments Subcommittee of PTAC Meeting held 2 March 2012 (minutes for web publishing) Cancer Treatments Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology
More informationLung cancer is the leading cause of cancer-related death in the United
Evolving Treatment Paradigms in Non-Small Cell Lung Cancer MARGARET E. M. VAN METER, MD Medical Oncology Fellow Division of Cancer Medicine The University of Texas M.D. Anderson Cancer Center Houston,
More informationIs there a positive effect of participation on a clinical trial for patients with advanced nonsmall cell lung cancer?
Original Article Is there a positive effect of participation on a clinical trial for patients with advanced nonsmall cell lung cancer? Rajappa S, Gundeti S, Uppalapati S, Jiwatani S, Abhyankar A, Pal C,
More informationManagement of stage III A-B of NSCLC. Hamed ALHusaini Medical Oncologist
Management of stage III A-B of NSCLC Hamed ALHusaini Medical Oncologist Global incidence, CA cancer J Clin 2011;61:69-90 Stage III NSCLC Includes heterogeneous group of patients with differences in the
More informationStage I, II Non Small Cell Lung Cancer
Stage I, II Non Small Cell Lung Cancer Best Results T1 (less 3 cm) N0 80% 5 year survival No Role Adjuvant Chemotherapy Radiation Therapy Reduces Local Recurrence No Improvement in Survival 1 Staging Mediastinal
More informationA new score predicting the survival of patients with spinal cord compression from myeloma
A new score predicting the survival of patients with spinal cord compression from myeloma (1) Sarah Douglas, Department of Radiation Oncology, University of Lubeck, Germany; sarah_douglas@gmx.de (2) Steven
More informationKey words: chemotherapy; evidence-based medicine; guidelines; non-small cell lung cancer
Chemotherapeutic Management of Stage IV Non-small Cell Lung Cancer* Mark A. Socinski, MD, FCCP; David E. Morris, MD; Gregory A. Masters, MD, FCCP; and Rogerio Lilenbaum, MD Stage IV non-small cell lung
More informationGemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer
Gemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer Review Article [1] December 01, 2003 By George W. Sledge, Jr, MD [2] Gemcitabine (Gemzar) and paclitaxel show good activity as single
More informationRole of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases
Role of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases R. Shraddha, P.N. Pandit Radium Institute, Patna Medical College and Hospital, Patna, India Abstract NHL is a highly
More informationIMMUNOMEDICS, INC. February 2016. Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases February 2016 Forward-Looking Statements This presentation, in addition to historical information, contains certain
More informationClinical Trial Endpoints for the Approval of Non- Small Cell Lung Cancer Drugs and Biologics Guidance for Industry
Clinical Trial Endpoints for the Approval of Non- Small Cell Lung Cancer Drugs and Biologics Guidance for Industry U.S. Department of Health and Human Services Food and Drug Administration Center for Drug
More informationEvaluating the Efficiency of Targeted Designs for Randomized Clinical Trials
Vol. 0, 6759 6763, October 5, 004 Clinical Cancer Research 6759 Perspective Evaluating the Efficiency of Targeted Designs for Randomized Clinical Trials Richard Simon and Aboubakar Maitournam Biometric
More informationTreatment of Metastatic Breast Cancer: Endocrine Therapies. Robert W. Carlson, M.D. Professor of Medicine Stanford University
Treatment of Metastatic Breast Cancer: Endocrine Therapies Robert W. Carlson, M.D. Professor of Medicine Stanford University MDACC Experience with FAC in Chemotherapy-Naive MBC Greenberg et al, J Clin
More informationMetastatic Breast Cancer 201. Carolyn B. Hendricks, MD October 29, 2011
Metastatic Breast Cancer 201 Carolyn B. Hendricks, MD October 29, 2011 Overview Is rebiopsy necessary at the time of recurrence or progression of disease? How dose a very aggressive treatment upfront compare
More informationSystemic Chemotherapy for Advanced Non-Small Cell Lung Cancer: Recent Advances and Future Directions
Systemic Chemotherapy for Advanced Non-Small Cell Lung Cancer: Recent Advances and Future Directions Suresh Ramalingam, a Chandra Belani b a Lung & Thoracic Malignancies Program, University of Pittsburgh
More informationPOLICY A. INDICATIONS
Alimta (pemetrexed) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 09/01/2007 Current Effective Date: 10/01/2015 POLICY A. INDICATIONS The indications below
More informationSummary of treatment benefits
Risk Management Plan PEMETREXED Powder for concentrate for Solution for infusion Pemetrexed is also indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non small cell
More informationElderly Patients with Advanced Non-Small Cell Lung Cancer: What Treatment?
4 The Open Lung Cancer Journal, 2011, 4, 4-9 Open Access Elderly Patients with Advanced Non-Small Cell Lung Cancer: What Treatment? Antonio Rossi * Division of Medical Oncology, S.G. Moscati Hospital,
More informationTreatment of Stage IV Non-small Cell Lung Cancer
CHEST Supplement DIAGNOSIS AND MANAGEMENT OF LUNG CANCER, 3RD ED: ACCP GUIDELINES Treatment of Stage IV Non-small Cell Lung Cancer Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest
More informationALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials)
ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials) 3 Integrated Trials Testing Targeted Therapy in Early Stage Lung Cancer Part of NCI s Precision Medicine Effort in
More informationEfficacy analysis and graphical representation in Oncology trials - A case study
Efficacy analysis and graphical representation in Oncology trials - A case study Anindita Bhattacharjee Vijayalakshmi Indana Cytel, Pune The views expressed in this presentation are our own and do not
More informationREPORT ASCO 2011 CHICAG0 : RESPIRATORY ONCOLOGY Johan Vansteenkiste / Christophe Dooms, Univ. Hospital Leuven and Leuven Lung Cancer Group
1 REPORT ASCO 2011 CHICAG0 : RESPIRATORY ONCOLOGY Johan Vansteenkiste / Christophe Dooms, Univ. Hospital Leuven and Leuven Lung Cancer Group 10 MESSAGE HIGHLIGHTS Early stage non-small cell lung cancer
More informationNon Small Cell Lung Cancer: Scientific Discoveries and the Pursuit of Progress
Non Small Cell Lung Cancer: Scientific Discoveries and the Pursuit of Progress Lung Cancer Accounts for 14% of All New Cancer Diagnoses in the United States 1 Lung cancer is the second most common malignancy
More informationU.S. Food and Drug Administration
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA s website for reference purposes only. It was current when produced, but is no longer maintained
More informationA new predictive algorithm for aiding clinical decision-making in lung cancer
Better Care. Faster A new predictive algorithm for aiding clinical decision-making in lung cancer Y Kogan, I Sela, Y Kheiffetz, M Kleiman, Z Agur, Optimata Ltd., O Liran, N Peled, Sheba hospital, I Lazarev,
More informationTreatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost-Effectiveness
Department of Veterans Affairs Health Services Research & Development Service Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost-Effectiveness
More informationWhat is the reference cytotoxic regimen in advanced gastric cancer?
What is the reference cytotoxic regimen in advanced gastric cancer? Florian Lordick Professor of Oncology Director of the University Cancer Center Leipzig (UCCL) Germany What we know from clinical research.
More informationThe Impact of Palliative Care and Hospice Services in the Care of Patients with Advanced Stage Non-Small Cell Lung Cancer
The Impact of Palliative Care and Hospice Services in the Care of Patients with Advanced Stage Non-Small Cell Lung Cancer Richard C. Stephenson, MD Hospice & Palliative CareCenter Amy H. Hughes Forsyth
More informationSystemic Therapy for Stage IV Non-Small Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
Systemic Therapy for Stage IV Non-Small Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Introduction The purpose of this guideline update is to revise the 2011
More informationAdjuvant Therapy Non Small Cell Lung Cancer. Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015
Adjuvant Therapy Non Small Cell Lung Cancer Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015 No Disclosures Number of studies Studies Per Month 12 10 8 6 4 2 0 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3
More informationTemporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008
Special Report Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008 Matthew B. Schabath, PhD, Zachary J. Thompson, PhD,
More informationKey words: epidermal growth factor receptor; lung cancer; targeted therapy; tyrosine kinase inhibitor
Targeted Therapy for the Treatment of Advanced Non-small Cell Lung Cancer* A Review of the Epidermal Growth Factor Receptor Antagonists Gerard A. Silvestri, MD, FCCP; and M. Patricia Rivera, MD, FCCP Lung
More informationMetastatic breast cancer, HER2 overexpression, first-line therapy in combination with a taxane and trastuzumab
COMPENDIA TRANSPARENCY TRACKING FORM DRUG: Carboplatin INDICATION: Metastatic breast cancer, HER2 overexpression, first-line therapy in combination with a taxane and trastuzumab COMPENDIA TRANSPARENCY
More informationConsiderations and Challenges in Treating Elderly Patients with Lung Cancer, by Dr. Rogerio Lilenbaum
Considerations and Challenges in Treating Elderly Patients with Lung Cancer, by Dr. Rogerio Lilenbaum Dr. West: Hello, and welcome. My name is Dr. Jack West, and I m a medical oncologist in Seattle Washington
More informationDecision to Continue the Development of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer to be Announced
September 27, 2013 ONO PHARMACEUTICAL CO., LTD. Corporate Communications Phone: +81-6-6263-5670 Decision to Continue the Development of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer to be Announced
More informationSmall-Cell Lung Cancer: Is There a Standard Therapy?
Small-Cell Lung Cancer: Is There a Standard Therapy? Review Article [1] January 02, 1998 By Pieter E. Postmus, MD, PhD [2] and Egbert F. Smit, MD [3] For more than 25 years, chemotherapy has been the cornerstone
More informationTreating Patients with Hormone Receptor Positive, HER2 Positive Operable or Locally Advanced Breast Cancer
Breast Studies Adjuvant therapy after surgery Her 2 positive Breast Cancer B 52 Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients with Hormone
More informationChing-Yao Yang, Yu-Wen Tien
Ching-Yao Yang, Yu-Wen Tien Division of General Surgery, Department of Surgery, National Taiwan University Hospital Oct-30-2010 Pancreatic NET have poorer prognosis when presence of liver metastases at
More informationCLINICAL POLICY Department: Medical Management Document Name: Opdivo Reference Number: CP.PHAR.121 Effective Date: 07/15
Page: 1 of 6 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted
More informationOvarian Cancer (Event Driven)
Brochure More information from http://www.researchandmarkets.com/reports/2367241/ Ovarian Cancer (Event Driven) Description: Owing to the lack of screening programs across the markets under study, ovarian
More informationName of Policy: Molecular Analysis for Targeted Therapy of Non-Small-Cell Lung Cancer (NSCLC)
Name of Policy: Molecular Analysis for Targeted Therapy of Non-Small-Cell Lung Cancer (NSCLC) Policy #: 468 Latest Review Date: October 2015 Category: Laboratory Policy Grade: B Background/Definitions:
More information